Crunkhorn SarahNat Rev Drug DiscovNature Reviews Drug DiscoverySarah, C. Immunotherapy: CAR T cells in glioblastoma. Nat. Rev. Drug Discov. 2017, 16, 602. [CrossRef] [PubMed]Immunotherapy:CAR T cells in glioblastoma. SARAH C. Nature Reviews Drug Discovery . 2017...
Will CAR T cells or other CAR cells replace chemotherapy for some? Time will tell. Paul Lin, MD, of MD Anderson Cancer Center, spoke on CAR cells being introduced into other immune effector cells. And he showed that CAR-NK (natural killer) cells can be used to treat DLBCL, and that b...
Chimeric antigen receptor T-cells (CAR-Ts) are T lymphocytes that have been genetically engineered to express synthetic CAR molecules on their surface. CAR molecules endow T lymphocytes with the proficiency to recognize cell surface target antigens of interest and mediate exclusive cytotoxicity against ...
L. CAR T cells for infection, autoimmunity and allotransplantation. Nat. Rev. Immunol. 18, 605–616 (2018). CAS PubMed PubMed Central Google Scholar Rosado-Sanchez, I. & Levings, M. K. Building a CAR-Treg: going from the basic to the luxury model. Cell Immunol. 358, 104220 (...
Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy, specifically, has now made it possible to target LOH with T cells, according to the press release. CARs are engineered receptors that bind to specific antigens on the surface of cancer cells, which mark the cancer cell for ...
Although CAR T cells can be effective in some patients with CLL, including some who are refractory to other therapies, there's certainly room for improvement. I'm optimistic about some of the combination data that are emerging. For example, the addition of ibrutinib to CAR T-cell therapy may...
When a cancer patient is being treated with CAR-T cell therapy, clinicians collect T cells from the patient's blood or from a healthy donor. Then, they alter these cells in the lab, adding DNA that coaxes the immune cells into producing special, cancer-recognizing chimeric antigen receptors...
Herein, we present the design of light-switchable CAR (designated LiCAR) T cells that allow real-time phototunable activation of therapeutic T cells to precisely induce tumour cell killing. When coupled with imaging-guided, surgically removable upconversion nanoplates that have enhanced near-infrared-...
BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells In a patient with treatment-refractory idiopathic inflammatory myositis, re-infusion of CD19 CAR-T cells following disease relapse led to the development of anti-CD19 CAR T cells and no clinic...
Marcela V. Maus, MD, PhD, evaluates the next generation of chimeric antigen receptor (CAR) T cells in both hematologic malignancies and solid tumors